![](/img/cover-not-exists.png)
PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Smare, C., Dave, K., Juarez-Garcia, A., Schoenherr, N., Abraham, P., Penrod, J.R., Camidge, D.R., Yuan, Y.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.431
Date:
November, 2019
File:
PDF, 317 KB
english, 2019